Nasdaq-listed Jupiter Neurosciences acquires exclusive U.S. rights to ALA-002, expanding its CNS pipeline with a potential $100 million agreement.
Jupiter Neurosciences (Nasdaq: JUNS) announced a definitive licensing agreement with PharmAla Biotech, granting it perpetual exclusive U.S. rights to ALA-002, a patented MDMA formulation. The deal is valued at up to $100 million, including milestone payments, and positions Jupiter as a dual clinical-stage central nervous system (CNS) company.